Comparative Pharmacology
Head-to-head clinical analysis: GILOTRIF versus NERLYNX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GILOTRIF versus NERLYNX.
GILOTRIF vs NERLYNX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GILOTRIF (afatinib) is an irreversible inhibitor of the ErbB family of tyrosine kinases, including EGFR (ErbB1), HER2 (ErbB2), ErbB3, and ErbB4. It binds covalently to the ATP-binding pocket of the kinase domain, blocking downstream signaling pathways involved in cell proliferation, survival, and angiogenesis.
Neratinib is an irreversible pan-ErbB receptor tyrosine kinase inhibitor that inhibits EGFR, HER2, and HER4, leading to reduced downstream signaling and cell proliferation.
40 mg orally once daily for first-line treatment of EGFR mutation-positive non-small cell lung cancer; may be increased to 50 mg if tolerated.
NERLYNX (neratinib) 240 mg (6 tablets of 40 mg) orally once daily with food for a total duration of 1 year.
None Documented
None Documented
Terminal elimination half-life is approximately 41 hours, supporting once-daily dosing. Steady-state is reached within 8 days.
Terminal half-life approximately 7–17 days (mean ~9 days) after a 240 mg daily dose, supporting once-daily dosing. Steady state reached by ~4–6 weeks.
Approximately 88% of the administered dose is eliminated via feces (with 85% as unchanged parent drug), and 8% via urine (with <5% as unchanged drug). Biliary excretion is the primary route for unchanged drug.
Primarily hepatic metabolism; 97% of dose recovered in feces (including unchanged drug and metabolites), <1% in urine as unchanged drug. Biliary excretion is a major route.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor